CHARACTERIZATION OF INFLUENZA B VIRUS VARIANTS WITH REDUCED NEURAMINIDASE INHIBITOR SUSCEPTIBILITY

HIV / AIDSViral Infections, Non-HIV

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

Antiviral Res.

Hu Y, Zhang J, Musharrafieh RG, Ma C, Hau R, Wang J

doi: 10.1016/

SPECIAL REPORT

HIV / AIDS

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

Viral Infections, Non-HIV

Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses

Antimicrob Agents Chemother.

Vigil A, Estélles A, Kauvar LM, Johnson SK, Tripp RA, Wittekind M

doi: 10.1128/AAC.02269-17.

Viral Infections, Non-HIV

Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study

Clin Infect Dis

Komeda T, Takazono T, Hosogaya N, Ogura E, Fujiwara M, Miyauchi H, Ajisawa Y, Iwata S, Watanabe H, Honda K, Kitanishi Y, Hara K, Mukae H

doi: 10.1093/cid/ciaa1622

Viral Infections, Non-HIV

Antivirals targeting the polymerase complex of influenza viruses

Antiviral Res.

Mifsud EJ, Hayden FG, Hurt AC

doi: 10.1016/j.antiviral.2019.104545.

SPECIAL REPORT

HIV / AIDS

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021

Viral Infections, Non-HIV

H3N2 Influenza Viruses in Humans: Viral Mechanisms, Evolution, and Evaluation

Hum Vaccin Immunother.

Allen JD, Ross TM

doi: 10.1080/

Viral Infections, Non-HIV

Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018-2019

Vaccine.

Melidou A, Hungnes O, Pereyaslov D, Adlhoch C, Segaloff H, Robesyn E, Penttinen P, Olsen SJ, European Region influenza surveillance network.

doi: 10.1016/j.vaccine.2020.06.031.

Viral Infections, Non-HIV

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

Lancet Respir Med.

Davey RT Jr, Fernández-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, Khurana S, Engen N, Gordin F, Jain MK, Kan V, Polizzotto MN, Riska P, Ruxrungtham K, Temesgen Z, Lundgren J, Beigel JH, Lane HC, Neaton JD, INSIGHT FLU-IVIG Study Group.

doi: 10.1016/S2213-2600(19)30253-X.

Related content

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses

Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study

Antivirals targeting the polymerase complex of influenza viruses

11e Conférence de la Société internationale sur le SIDA (IAS) 2021

H3N2 Influenza Viruses in Humans: Viral Mechanisms, Evolution, and Evaluation

Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018-2019

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021